Basic Information
| LncRNA/CircRNA Name | LINC00857 |
| Synonyms | LINC00857 |
| Region | GRCh38_10:80207710-80219657 |
| Ensemble | ENSG00000237523 |
| Refseq | NR_038464 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | platinum | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR etc. |
| Sample | cell lines (UM??C?? (ATCC: CRL??749) and T24 (ATCC: HTB??)) |
| Expression Pattern | differential expression |
| Function Description | Furthermore, LINC00857 knockdown sensitized UM-UC-3 and T24 bladder cancer cells to cisplatin, via the negative regulation of the LMAN1 gene. Our data indicate that LINC00857 plays an important role in the regulation of response to platinum-based chemotherapy. |
| Pubmed ID | 29856124 |
| Year | 2018 |
| Title | LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer |
External Links
| Links for LINC00857 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |